Literature DB >> 19272843

Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry.

Sung-Su Kim1, Heon-Woo Lee, Kyung-Tae Lee.   

Abstract

A simple liquid chromatography/tandem mass spectrometry (LC/MS/MS) method with electrospray ionization in positive ion multiple reaction monitoring mode was developed for the quantification of mazindol (an anorectic agent) in human plasma. Fluoxetine was adopted as an internal standard (IS), and sample preparation involved one-step liquid/liquid extraction using ethyl acetate. The transition monitored were m/z 285>44 for mazindol and m/z 310>44 for IS. Chromatographic separation was achieved on a Capcell Pak MGII C(18) column using an isocratic mobile phase, consisting of acetonitrile-20mM ammonium formate in water (50:50, v/v, adjusted to pH 3.5 with formic acid) at a flow-rate of 0.2mL/min. The retention times of mazindol and fluoxetine were 1.03min and 1.45min, respectively. The lower limit of quantitation (LLOQ) was 0.1ng/mL using 200microL of plasma, and no interferences were detected in chromatograms. The bench top stability of mazindol was evaluated in buffered and non-buffered plasma. The selectivity, linearity, precision, accuracy, recovery, and stability of the devised method were fully validated and absolute and relative matrix effects were evaluated. The described method provides a fast and sensitive analytical tool for determining mazindol levels in plasma, and was successfully applied to a pharmacokinetic study in 24 healthy human subjects after oral administration of 2mg tablet formulation of mazindol under fasting conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19272843     DOI: 10.1016/j.jchromb.2009.02.049

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers.

Authors:  Marcella Herbstrith de Oliveira; Pâmela Cristina Lukasewicz Ferreira; Graciela Carlos; Fernanda Rodrigues Salazar; Ana Maria Bergold; Flavio Pechansky; Renata Pereira Limberger; Pedro Eduardo Fröehlich
Journal:  Eur J Clin Pharmacol       Date:  2016-04-12       Impact factor: 2.953

2.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.